Dasabuvir (ABT333) for the treatment of chronic HCV genotype I: a new face of cure, an expert review

References

• Kanwal F, Hoang T, Kramer JR, et al. Increasing prevalence of HCC and cirrhosis in patients with chronic hepatitis C virus infection. Gastroenterology. 2011;140(4):1182-8; e.
   PubMed Web of Science ®Google Scholar
• Maasoumy B, Wedemeyer H. Natural history of acute and chronic hepatitis C. Best Pract Res Clin Gastroenterol. 2012;26:401–412.
   PubMed Web of Science ®Google Scholar
• Ferrari SM, Fallahi P, Mancusi C, et al. HCV- related autoimmune disorders in HCV chronic infection. Clin Ter. 2013;164:e305–12.
   PubMed Web of Science ®Google Scholar
• Kiser JJ, Flexner C. Direct-acting antiviral agents for hepatitis C virus infection. Annu Rev Pharmacol Toxicol. 2013;53:427–449.
   PubMed Web of Science ®Google Scholar
• Borgia G, Reynauds L, Gentile I, et al. Myasthenia gravis during low dose IFN alpha therapy for chronic hepatitis C. j Interferon. Cytokine Res. 2001;21(7):469–470.
   PubMed Web of Science ®Google Scholar
• Gentile I, Viola C, Reynaud L, et al. Hemolytic anemia during Pegylated IFN-alpha 2b plus ribavirin treatment for chronic hepatitis C: ribavirin is not always the culprit. J Interferon Cytokine Res. 2005;25(5):283–285.
   PubMed Web of Science ®Google Scholar
• Tosone G, Borgia G, Gentile I, et al A case of Pegylated interferon alpha-related diabetic ketoacidosis: can this complication be avoided?. Acta Diabetol. 2007;44(3):167–169.
   PubMed Web of Science ®Google Scholar
• Gentile Viola C, Borgia F, et al. The efficacy and safety of telaprevir-a new protease inhibitor gainst hepatitis C virus. Expert Opin Investig Drugs. 2010;19(1):151–159.
   PubMed Web of Science ®Google Scholar
• Ghany MG, Strader DB, Thomas DL, et al.. Diagnosis, management and treatment of hepatitis C: an update. Hepatology. 2009;49(4):1335–1374.
   PubMed Web of Science ®Google Scholar
• Coppola N, Pisaturo M, Sagnelli C, et al Peg-interferon plus ribavirin with or without boceprevir or telaprevir for HCV Genotype 1: a meta-analysis on the role of response predictors. PLoS ONE. 2014;9:4.
   Google Scholar
• Gentile I, Buonomo AR, Borgia G. Dasabuvir: a non-nucleoside inhibitor of NS5B for the treatment of Hepatitis C virus infection. Rev Recent Clin Trials. 2014;9:115–123.
   PubMedGoogle Scholar
• Pockros PJ. Nucleoside/Nucleotide analogue polymerase inhibitors in development. Clin Liver Dis. 2013;17:105–110.
   PubMed Web of Science ®Google Scholar
• Au JS, Pockros PJ. Novel therapeutic approaches for hepatitis C. Clin Pharmacol Ther. 2014;95(1):78–88.
   PubMed Web of Science ®Google Scholar
• Soriano V, Vispo E, De Mendoza C, et al Hepatitis C therapy with HCV NS5B polymerase inhibitors. Expert Opin Pharmacother. 2013;14:1161–1170.
   PubMed Web of Science ®Google Scholar
• Kwo PY, Vinayek R. The therapeutic approaches for hepatitis C virus: protease inhibitors and polymerase inhibitors. Gut Liver. 2011;5(4):406–417.
   PubMed Web of Science ®Google Scholar
• Manns MP, Von Hahn T. Novel therapies for hepatitis C-one pill fits all?. Nat Rev Drug Discov. 2013;12(8):595–610.
   PubMed Web of Science ®Google Scholar
• Maring C, Wagner R, Hutchinson D, et al. Preclinical potency, pharmacokinetic and ADME characterization of ABT-333,a novel non- nucleoside HCV polymerase inhibitor. J Hepatol. 2009;50:S347–S.
   Web of Science ®Google Scholar
• Zeuzem S, Jacobson IM, Baykal T, et al. Retreatment of HCV with ABT-450/rombitasv and dasabuvir with ribavirin. N Engl J Med. 2014;370(17):1604–1614.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Torres M, Lawitz E, Cohen D. Treatment-naïve, HCV genotype 1-infected subjects show significantly greater HCV RNA decreases when treated with 28 days of ABT-333 plus peg interferon and ribavirin compared to peg interferon and ribavirin alone. Hepatology. 2009;50(Suppl 4):91A.
   Google Scholar
• Poordad F, Hezode C, Trinh R, et al. ABT-450/r-ombitasvir and Dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med. 2014;370(21):1973–1982.
   PubMed Web of Science ®Google Scholar
• Kwo PY, Mantry PS, Coakley E, et al. An interferon-free antiviral regimen for HCV after liver transplantation. N Engl J Med. 2014;371:2375–2382.
   PubMed Web of Science ®Google Scholar
• Ferenci P, et al. ABT-450/r-Ombitasvir and Dasabuvir with or without ribavirin for HCV. N Engl J Med. 2014;370(21):1983–1992. PEARL III and IV.
   PubMed Web of Science ®Google Scholar
• Ferenci P, Nyberg A, Enayati P, et al. PEARL III: 12 weeks of ABT-450/R/267 + ABT-333 achieved SVR in >99% of 419 treatment-naive HCV genotype 1B-infected adults with or without ribavirin. J Hepatol. 2014;60(1):S527.
   Web of Science ®Google Scholar
• Feld JJ, Kowdley KV, Coakley E, et al Treatment of HCV with ABT-450/r-Ombitasvir and dasabuvir with ribavirin. N Engl J Med. 2014;370(17):1594–1603.
   PubMed Web of Science ®Google Scholar
• Gaultier I, Cohen D, Dumas E, et al. 12-week efficacy and safety of ABT-072 or ABT-333 with Pegylated interferon + ribavirin, following 3-day monotherapy in genotype 1 HCV infected treatment-naive subjects [abstract1329]. 21st Conference of the Asian Pacific Association for the Study of the Liver (APASL); 17 – 20 February2011; Bangkok, Thailand.
   Google Scholar
• Pilot-Matias T, Koev G, Krishnan P, et al. In vitro combinatory effect of HCV NS3/4A protease inhibitor ABT-450, NS5A inhibitor ABT-267 and non nucleoside NS5B polymerase inhibitor ABT-333. J Hepatol. 2012;56:S338–S38.
   Web of Science ®Google Scholar
• Eron JJ, Lalezari J, Slim J, et al. Safety and efficacy of Ombitasvir - 450/r and dasabuvir and ribavirin in HCV/HIV-1 co-infected patients receiving atazanavir or raltegravir ART regimens. J Int AIDS Soc. 2014;17(4 Suppl 3):19500.
   PubMed Web of Science ®Google Scholar
• Poordad F, Lawitz E, Kowdley KV, et al. Exploratory study of oral combination antiviral therapy for hepatitis C. N Engl J Med. 2013;368(1):45–53.
   PubMed Web of Science ®Google Scholar
• Kowdley KV, Lawitz E, Poordad F, et al. Phase 2b trial of interferon-free therapy for hepatitis C Virus genotype 1. N Engl J Med. 2014;370(3):222–232.
   PubMed Web of Science ®Google Scholar